Two dividend stocks you should add for retirement income
Two dividend stocks you should add for retirement income
Two standout retirement dividend stocks — AbbVie (ABBV) and Johnson & Johnson (JNJ) — combine reliable income, dividend growth streaks, and defensive business models that hold up in market downturns. Together, they offer a 2.7% and 2.1% yield respectively, backed by free cash flow yields that actually those dividends.
Side-by-Side Snapshot
| Metric | AbbVie (ABBV) | Johnson & Johnson (JNJ) |
|---|---|---|
| Price | $253.38 | $248.82 |
| Market Cap | $449.63B | $609.12B |
| Dividend Yield | 2.7% | 2.1% |
| Div / Share (Annual) | $6.92 | $5.36 |
| FCF Yield | 4.5% | 3.0% |
| Net Margin | 5.8% | 21.5% |
| P/E (LTM) | 124.5x | 28.5x |
| Fair Value | $254.58 | $262.91 |
| Fair Value Upside | +0.5% | +5.7% |
| Consecutive Div. Growth | 13 yrs | 60+ yrs |
AbbVie’s elevated P/E reflects acquisition-related amortization from its Allergan deal — operating cash generation is much stronger than net income implies.
AbbVie — The Income Engine
AbbVie (ABBV) is the higher-yielding pick at 2.7%, with a dividend per share of $6.92 annually. The stock has raised its dividend for 13 consecutive years — including through the post-Humira patent cliff that many feared would derail it entirely. Instead, Skyrizi and Rinvoq have more than filled the gap, pushing revenue from $56.2B (FY2022) to $61.16B (FY2026). The 4.5% FCF yield is the real signal here — it confirms the dividend is well-covered by actual cash, not just accounting earnings.
Bull case: Pipeline diversification, neuroscience acquisitions, and global pharma exposure make this a durable income compounder.
Bear case: Modest near-term fair value upside (+0.5%) and 12 downward earnings revisions suggest near-term expectations are being tempered.
Johnson & Johnson — The Stability Anchor
Johnson & Johnson (JNJ) is a true Dividend King — 60+ consecutive years of dividend increases, through recessions, pandemics, and market crises. With a 21.5% net margin, $609B market cap, and revenue growing steadily to $94.19B, this is as close to a "sleep well at night" dividend stock as the market offers. Fair value sits at $262.91, implying +5.7% upside from current prices — meaning you’re getting growth potential income.
Bull case: MedTech and Innovative Medicine segments both growing, rock-solid balance sheet, and a 3.0% FCF yield that easily supports the payout.
Bear case: Trading at 28.5x earnings isn’t cheap; slower growers rarely re-rate sharply higher.
Why Both Work Together
They’re complementary, not redundant. AbbVie brings higher yield and faster dividend growth momentum; J&J brings institutional-grade stability and 6 decades of unbroken raises. For a retirement portfolio, that combination means income today purchasing-power protection over time — the two things fixed income alone rarely delivers.
Historical data is limited to 10 years on Pro+ plan.